RGEN REPLIGEN CORP

CIK 0000730272 47 ready 8-Ks latest July 28, 2026, 7:13 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 47

Latest filing July 28, 2026, 7:13 AM ET

Top materiality 0.90

Event mix earnings ×21 · leadership ×10 · m_and_a ×6

Sentiment 19 pos · 7 neg · 21 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for RGEN

Highest-materiality recent filing

Repligen to acquire BioLife Solutions for ~$1.5B; reports preliminary Q2 revenue growth of ~12%

July 22, 2026, 8:56 AM ET M&A materiality 0.90 positive item 1.01 item 2.02 item 7.01 item 8.01 item 9.01

Repligen to acquire BioLife for ~$1.5B; per share consideration $31.00 ($11.25 cash + 0.1442 RGEN shares).
Deal expected to close Q4 2026; boards unanimously approved; subject to BLFS stockholder approval and HSR clearance.

Read filing →

July 28, 2026, 7:13 AM ET earnings materiality 0.85 positive item 2.02 item 9.01

Repligen Q2 revenue $204M (+13% organic), adj EPS $0.54; raises FY guidance; acquires BioLife

Q2 revenue $204M, +12% reported, +13% organic; adjusted EPS $0.54 vs $0.37 prior year.
July 22, 2026, 8:56 AM ET M&A materiality 0.90 positive item 1.01 item 2.02 item 7.01 item 8.01 item 9.01

Repligen to acquire BioLife Solutions for ~$1.5B; reports preliminary Q2 revenue growth of ~12%

Repligen to acquire BioLife for ~$1.5B; per share consideration $31.00 ($11.25 cash + 0.1442 RGEN shares).
May 5, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Repligen Q1 revenue $194M (+11% organic); raises adjusted EPS guidance to $1.97-$2.05

Q1 revenue $194M, +15% reported/+11% organic; GAAP EPS $0.15, adjusted EPS $0.48 (+23% YoY).
February 24, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Repligen Q4 revenue $198M (+18%); FY26 guidance $810-840M

Q4 revenue $198M, up 18% reported and 14% organic YoY; full year 2025 revenue $738M (+16% reported and organic non-COVID).
October 28, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Repligen Q3 revenue $189M (+22% YoY); raises FY2025 guidance to $729-737M

Revenue $189M, +22% reported, +18% organic; double-digit growth across all franchises.
July 29, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Repligen Q2 revenue $182M (+17% organic non-COVID); orders >20% YoY; raises FY guidance

Revenue $182M, up 15% reported and 17% organic non-COVID YoY.
April 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Repligen Q1 revenue $169M (+10% YoY); adjusted EPS $0.39 vs $0.30; orders up high-teens

Revenue $169M, up 10% reported, 14% organic non-COVID YoY; GAAP EPS $0.10, adjusted EPS $0.39.
February 20, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Repligen Q4 revenue $168M; FY2024 $634M; guides FY2025 8-12% growth

Q4 revenue $168M, flat YoY; FY2024 revenue $634M vs $632M.
November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Repligen Q3 revenue $155M (+10% YoY); adjusted EPS $0.43 vs $0.23

GAAP net loss ($0.7M) vs income $17M; adjusted net income $24M vs $13M.
September 18, 2024, 7:59 PM ET other material materiality 0.75 negative item 2.02 item 7.01 item 4.02 item 9.01

Repligen restates financials for 2023-2024 due to $17.3M revenue timing error; material weakness identified

Restatement covers Q1'23 through Q2'24; $17.3M payment from cancelled COVID orders was mis-timed.
July 30, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Repligen Q2 revenue $154M, adj. EPS $0.33, orders $157M; CEO transition, Tantti acquisition

Q2 2024 revenue $154M vs $159M prior year; GAAP EPS $0.06, adjusted EPS $0.33 vs $0.53.
June 14, 2024, 7:59 PM ET leadership materiality 0.75 neutral item 5.02 ◈ executive_change ×4

Repligen appoints Olivier Loeillot as CEO effective Sept 1, 2024; Hunt becomes Executive Chair

Loeillot receives $750K base salary, 85% target bonus, and a $5M equity award (50% RSUs, 25% options, 25% PSUs).
June 13, 2024, 7:59 PM ET leadership materiality 0.70 positive item 7.01 item 9.01

Repligen CEO Tony Hunt to become Executive Chair; Olivier Loeillot appointed President and CEO effective Sept 1, 2024

Tony Hunt transitions from CEO to Executive Chair effective Sept 1, 2024; Olivier Loeillot named President and CEO.
May 1, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Repligen Q1 revenue falls 17% to $151M; GAAP EPS $0.04, adjusted EPS $0.28

Q1 revenue $151.3M, down from $182.7M YoY; GAAP net income $2.1M ($0.04 diluted EPS) vs $28.8M ($0.51).
February 21, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Repligen Q4 revenue down 16.6% to $155.7M; net loss $0.46/share

Q4 2023 revenue $155.7M vs $186.8M in Q4 2022; full year $638.8M vs $801.5M.
December 7, 2023, 6:59 PM ET debt materiality 0.70 neutral item 3.02 item 8.01 item 9.01

Repligen issues $600M of 1% convertible notes due 2028, exchanges $217.7M of 2024 notes

Issues $600M aggregate 1.00% Convertible Senior Notes due 2028; $309.9M exchanged for $217.7M of 0.375% notes due 2024, $290.1M for cash.
October 31, 2023, 7:59 PM ET earnings materiality 0.78 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Repligen Q3 revenue $141.2M (-30% YoY); narrows FY2023 outlook, sees order recovery

Total revenue $141.2M, base business $140.1M; GAAP EPS $0.32, adjusted EPS $0.23.
September 26, 2023, 7:59 PM ET M&A materiality 0.75 positive item 7.01 item 8.01 item 9.01

Repligen to acquire Metenova for cash and equity; adds magnetic mixing technology

Metenova projected FY2023 revenue $24-25M; ~50 employees; magnetic mixers for bioprocess.
September 12, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change ×2

Repligen appoints Jason K. Garland as CFO, replacing retiring Jon Snodgres

Garland (ex-Integer CFO) named CFO effective Sept 25, 2023; Snodgres remains advisor through Oct 6.
August 2, 2023, 7:59 PM ET earnings materiality 0.88 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Repligen Q2 revenue down 23%; slashes FY2023 revenue guidance to $635-$665M

Q2 total revenue $159.2M (-23.3% YoY); base business revenue down 8.7%.
May 2, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Repligen Q1 revenue $182.7M, down 12% YoY; cuts full-year guidance on macro headwinds

GAAP EPS $0.51 (down 37% YoY); adjusted EPS $0.64 (down 30% YoY); gross margin 55.2% (down 520 bps).
April 12, 2023, 7:59 PM ET M&A materiality 0.60 neutral item 7.01 item 8.01 item 9.01

Repligen announces acquisition of FlexBiosys for undisclosed cash, equity, and earnout

Repligen executed Equity Purchase Agreement to acquire all outstanding equity of FlexBiosys.
February 22, 2023, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Repligen Q4 revenue flat YoY at $186.8M; guides 2023 revenue down 5% to $760-800M

Q4 GAAP EPS $0.85 (up from $0.50 YoY); adjusted EPS $0.68 (down from $0.81).
November 1, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Repligen Q3 revenue $200.7M (+13% YoY); raises FY revenue guidance to $795-$805M

Revenue $200.7M, +13% reported, +19% constant currency, +16% organic; base business up 29% YoY.
August 2, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Repligen Q2 revenue $207.6M (+27% YoY); raises FY 2022 guidance

Q2 revenue $207.6M, up 27% as reported, 32% constant currency; organic growth 29%.
June 1, 2022, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 5.07 item 8.01 item 9.01 ◈ executive_change

Repligen appoints Dr. Konstantin Konstantinov to board; all directors re-elected at annual meeting

Konstantinov elected to board effective May 26, 2022; brings 30 years of bioprocessing expertise from Genzyme and Bayer.
April 27, 2022, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Repligen Q1 revenue $206.4M (+45% YoY); lowers FY2022 revenue guidance on COVID decline

Record Q1 revenue of $206.4M (+45% YoY); GAAP EPS $0.81, adjusted EPS $0.92.
February 17, 2022, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Repligen Q4 revenue $186.5M (+72% YoY); FY 2022 guidance $800-830M (19-24% growth)

Q4 revenue $186.5M (+72% YoY, organic +69%); GAAP EPS $0.50, adjusted EPS $0.81.
December 16, 2021, 6:59 PM ET M&A materiality 0.70 neutral item 7.01 item 8.01 item 9.01

Repligen acquires Bio-Flex Solutions and Newton T&M for cash; terms undisclosed

Acquired all outstanding equity interests in Bio-Flex Solutions and Newton T&M effective Dec 16, 2021.
October 28, 2021, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Repligen Q3 revenue $178.2M (+89% YoY); raises FY 2021 revenue guidance to $655-665M

Revenue hit a record $178.2M in Q3 2021, up 89% YoY as reported and 77% organically.
September 16, 2021, 7:59 PM ET M&A materiality 0.70 positive item 7.01 item 8.01 item 9.01

Repligen to acquire Avitide for ~$150M in cash and stock, adding affinity chromatography capabilities

Total consideration ~$150M, consisting of $75M cash and $75M in Repligen common stock, plus three-year earnout.
July 27, 2021, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Repligen Q2 revenue $163M (+86% YoY); adj. EPS $0.79; raises FY21 outlook

Q2 revenue $163.0M, up 86% YoY as reported and 69% organic; base business grew 35% YoY.

Executive changes

Role change

Tony J. Hunt

Executive Chair

RGEN · REPLIGEN CORP

Effective: 2024-09-01
Successor: Olivier Loeillot
Filed: June 14, 2024, 7:59 PM ET

Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors

Appointed

Olivier Loeillot

President and Chief Executive Officer

RGEN · REPLIGEN CORP

Effective: 2024-09-01
Filed: June 14, 2024, 7:59 PM ET

Repligen has appointed Olivier Loeillot, Repligen’s President and Chief Commercial Officer, to the role of President and Chief Executive Officer, as successor to Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors (the “Board”), with such transition to be effective September 1, 2024

Role change

Karen A. Dawes

Lead Independent Director

RGEN · REPLIGEN CORP

Effective: 2024-09-01
Filed: June 14, 2024, 7:59 PM ET

appointed Karen A. Dawes, the Board’s current Chair, to the role of Lead Independent Director

Appointed

Olivier Loeillot

Member of the Board

RGEN · REPLIGEN CORP

Effective: 2024-09-01
Filed: June 14, 2024, 7:59 PM ET

the Board elected Mr. Loeillot as a member of the Board

Appointed

Margaret A. Pax

Director

RGEN · REPLIGEN CORP

Effective: 2024-03-18
Filed: March 19, 2024, 7:59 PM ET

the Board elected Margaret A. Pax to the Board, effective immediately (the “Effective Date”).

Role change

Tony Hunt

President

RGEN · REPLIGEN CORP

Effective: 2023-10-02
Successor: Olivier Loeillot
Filed: October 2, 2023, 7:59 PM ET

In connection with Mr. Hunt’s and the rest of the Board’s appointment of Mr. Loeillot’s as President and Chief Commercial Officer, Mr. Hunt will relinquish his role of President, effective October 2, 2023.

Appointed

Olivier Loeillot

President and Chief Commercial Officer

RGEN · REPLIGEN CORP

Effective: 2023-10-02
Filed: October 2, 2023, 7:59 PM ET

On October 2, 2023, Repligen Corporation (the “Company”) announced that Olivier Loeillot would be joining the Company as its President and Chief Commercial Officer, effective October 2, 2023 (the “Effective Date”).

Departed

Jon Snodgres

Chief Financial Officer

RGEN · REPLIGEN CORP

Effective: 2023-09-25
Successor: Jason K. Garland
Filed: September 12, 2023, 7:59 PM ET

replacing Jon Snodgres, who tendered his intention to retire on September 8, 2023 and who will continue in a full-time advisory role with the Company until October 6, 2023.

Appointed

Jason K. Garland

Chief Financial Officer

RGEN · REPLIGEN CORP

Effective: 2023-09-25
Filed: September 12, 2023, 7:59 PM ET

On September 12, 2023, Repligen Corporation (the “Company”) announced that Jason K. Garland would be joining the Company as its Chief Financial Officer, effective September 25, 2023 (the “Effective Date”), replacing Jon Snodgres, who tendered his intention to retire on September 8, 2023 and who will continue in a full-time advisory role with the Company until October 6, 2023.

Appointed

Martin Madaus

Director

RGEN · REPLIGEN CORP

Effective: 2023-02-06
Filed: February 9, 2023, 6:59 PM ET

the Board elected Martin Madaus, Ph.D. to the Board, effective February 6, 2023

Appointed

Konstantin Konstantinov

Director

RGEN · REPLIGEN CORP

Effective: 2022-05-26
Filed: June 1, 2022, 7:59 PM ET

the Board elected Konstantin Konstantinov, Ph.D. to the Board, effective May 26, 2022

Role change

James Bylund

Chief Operating Officer

RGEN · REPLIGEN CORP

Effective: 2022-01-01
Filed: January 4, 2022, 6:59 PM ET

On January 3, 2022, Repligen Corporation (the “ Company ”) promoted James Bylund, the Company’s current Senior Vice President, Operations and Information Technologies, to the role of Chief Operating Officer of the Company, effective January 1, 2022.

Earnings & guidance

2026-Q1 EPS reported $0.15 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event earnings

19 positive 7 negative 21 neutral

source · RGEN on sec.gov